Nimotuzumab

Generic Name: Nimotuzumab

Drug Type: Biotech

CAS Number: 780758-10-3

Unique Ingredient Identifier: 6NS400BXKH

Indication: Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions: Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck

Clinical Trials

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage

Interventions: Drug: Nimotuzumab

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT06509009

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Pancreatic Cancer

Interventions: Radiation: Stereotactic body radiation
Drug: Nimotuzumab
Drug: mono-chemotherapy

First Posted Date: 2024-05-20

Last Posted Date: 2024-05-20

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 73

Registration Number: NCT06422156

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Phase 2

Recruiting

Conditions: HCC

Interventions: Drug: Nimotuzumab
Drug: ICIs(Immune checkpoint inhibitors)

First Posted Date: 2024-05-14

Last Posted Date: 2024-05-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06413017

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Nimotuzumab
Drug: GX
Drug: Placebo

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 146

Registration Number: NCT06409429

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Nimotuzumab
Drug: AG

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06405685

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: nimotuzumab
Drug: AG chemotherapy

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06404840

Locations: 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Nimotuzumab
Drug: mFOLFIRINOX
Drug: GX

First Posted Date: 2024-04-29

Last Posted Date: 2024-10-31

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 57

Registration Number: NCT06389760

Locations: 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Completed

Conditions: Resectable Pancreatic Cancer

Interventions: Drug: Nimotuzumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 64

Registration Number: NCT06363084

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Phase 3

Not yet recruiting

Conditions: Refractory Metastatic Colorectal Cancer

Interventions: Drug: Nimotuzumab injection
Drug: Placebo
Drug: Trifluridine/tipiracil

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 420

Registration Number: NCT06343116

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Phase 3

Not yet recruiting

Conditions: Cervical Cancer

Interventions: Biological: Nimotuzumab
Drug: Cisplatin
Radiation: External Beam Radiotherapy (EBRT)
Radiation: Brachytherapy
Drug: placebo for Nimotuzumab

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT06333821

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy